Entering text into the input field will update the search result below

Beam gains 8% on collaboration with Pfizer to advance in vivo programs for rare diseases

Jan. 10, 2022 6:19 AM ETPfizer Inc. (PFE), BEAMBy: SA News Team7 Comments

two people meeting in bubble

We Are/DigitalVision via Getty Images

  • Beam Therapeutics (NASDAQ:BEAM) perks up 8% premarket after announcing an exclusive four-year research collaboration with Pfizer (NYSE:PFE), focused on in vivo base editing programs for three targets for rare genetic diseases of the

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.